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Abstract 
The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been developed to 
identify patients at high risk of mortality after an allograft. Reduced-intensity/non-myeloablative 
regimens have decreased the non-relapse mortality (NRM) in elderly and/or heavily pretreated 
patients. We performed a retrospective study to assess whether HCT-CI may predict clinical 
outcomes in a cohort of 203 patients with non-Hodgkin's (NHL; n=108), Hodgkin's lymphomas 
(HL; n=26), and multiple myeloma (MM; n=69), who were transplanted from a human leucocyte 
antigen (HLA)-matched sibling (n=121) or an unrelated donor (n=82) after a reduced-intensity 
regimen (n=154) or a low-dose total body irradiation-based non-myeloblative regimen (n=49). 
Cumulative incidence of NRM was 5, 16 and 20% at 1 year and 6, 24 and 27% at 2 years, for 
patients with an HCT-CI of 0, 1–2 and 3, respectively. By multivariate analysis, HCT-CI 
significantly predicted NRM (hazard ratio (HR)=1.6, P=0.03), overall survival (OS; HR=1.62, 
P<0.001) and progression-free survival (PFS; HR=1.43, P=0.002). Moreover, the Karnofsky 
performance status was also significantly associated with OS and NRM (HR=1.62, P<0.001 and 
HR=2.12, P=0.04, respectively). Conditioning type did not affect outcome after stratifying patients 
by HCT-CI. In the light of our study, all future prospective trials of the Gruppo Italiano Trapianti di 
Midollo (GITMO) will include the HCT-CI to stratify patients. 
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Introduction 
Reduced-intensity (RIC) and non-myeloablative conditionings have radically changed the eligible 
criteria for an allogeneic stem cell transplantation. Allografting in elderly patients and/or patients 
with non-hematological comorbidities is now characterized by a rather acceptable non-relapse 
mortality (NRM).
1, 2, 3, 4, 5
 Many of these patients have lymphomas and myeloma, and are elderly 
and heavily pretreated with several lines of chemotherapy, which frequently include an autograft. 
Although studies to further decrease NRM are in progress, valid tools to accurately assess 
transplant-related risks are needed. Moreover, the range of the intensity of the currently used 
conditionings varies greatly from low-dose (200 cGy) total body irradiation to several combinations 
of cytotoxic agents and there are not yet prospective studies that compare different regimens.
6, 7, 8
 
We and others have previously reported that age is no longer a risk factor for NRM after a RIC or a 
non-myeloablative allograft.
9, 10, 11
 Moreover, recent data have also shown that a RIC allograft is 
feasible in patients with lymphomas relapsed after an autograft.
12, 13
 
The Seattle group has recently proposed the hematopoietic cell transplantation comorbidity index 
(HCT-CI), derived from the Charlson comorbidity index that takes into account several 
pretransplant medical conditions that may specifically affect clinical outcomes after an allograft.
14, 
15
 Furthermore, the combination of the HCT-CI and the Karnofsky perfomance status (PS), which is 
a widely used measure of patient health status, has resulted in an accurate risk stratification for 
patients treated with a non-myeloablative allograft for various hematological malignancies.
16
 
In this retrospective multicenter study, we focused on patients with lymphomas and myeloma to 
investigate whether the HCT-CI, and secondly, Karnofsky PS were useful clinical parameters to 
predict outcome after a RIC or a non-myeloablative allograft. 
 Patients and methods 
Patients and conditioning regimens 
 
The analysis included 203 consecutive patients with non-Hodgkin's lymphoma (NHL), Hodgkin's 
lymphoma (HL) and multiple myeloma (MM) who underwent an allograft at three Italian transplant 
centers between 2001 and 2007. Informed consent was obtained at the time of transplantation in 
accordance to the Declaration of Helsinky. Patients not eligible for a standard myeloablative 
allograft because of age, presence of comorbidites or a previous autograft received either a RIC or a 
non-myeloablative conditioning regimen as per institutional or multicenter protocols. A non-
myeloablative conditioning regimen was defined as low-dose (200 cGy) total body irradiation 
with/without fludarabine, whereas RIC regimens were defined as combinations of fludarabine with 
cyclophosphamide, thiotepa or mephalan. 
Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate/cyclosporine with or 
without antithymocyte globulin and mycophenolate mofetil/cyclosporine for RIC and non-
myeloablative regimens, respectively. Diagnosis and clinical grade of acute and chronic GVHD 
were performed using international standard criteria.
17, 18
 Patients were transplanted from related or 
allele-matched unrelated donors. Human leucocyte antigen (HLA) typing was performed with either 
high- or low-resolution techniques for HLA-A, -B and -C antigens, whereas for HLA-DRB1 and 
DQB1 antigens, matching at the allele level was required. All patients received infection 
prophylaxis against fungi, bacteria, Pneumocystis carinii and Cytomegalovirus as per standard 
multicenter guidelines. 
Immune-suppression withdrawal followed by donor lymphocyte infusions was allowed for 
persistent, progressive or relapsed disease in the absence of GVHD. 
For lymphomas, pretransplant disease status and response were assessed with standard criteria by 
Cheson et al.
19, 20
 For MM, the International uniform response criteria were applied and patients in 
near-complete remission (CR) were included in the CR group.
21
 
The comorbidity scores and the Karnofsky PS were independently assigned by the principal 
investigators at each center using the HCT-CI and the Karnofsky scale after reviewing medical 
records and laboratory values of all patients.
14, 22
 All reviewed patients had complete clinical data, 
including pulmonary function tests that allowed to assess all comorbidities included in the HCT-CI. 
Statistical methods 
Overall survival (OS) was defined as the time from transplant to death for any cause. Progression-
free survival (PFS) was defined as the time from transplant to progression or relapse or death for 
any cause. Patients who responded to donor lymphocyte infusions were considered relapsed for 
time-to-event analysis. NRM was considered as death for any cause other than disease. OS and PFS 
were estimated using the Kaplan–Meier method. Comparisons of OS and PFS between groups were 
performed by the logrank test. NRM was defined as the probability of dying without previous 
disease recurrence, which was treated as a competing event. NRM and cumulative incidence of 
relapse (RI) were calculated by the cumulative incidence method, and comparisons between groups 
were analyzed by the Gray test. Multivariate analyses of NRM, OS and PFS were carried out with 
the Cox regression models, treating NRM and disease relapse or progression as competing events. 
All tests were two-sided. Correlations were evaluated by the Spearman's rank correlation test, 
considering a rho=0.3 as threshold for strong correlation. 
 
Results 
Pretransplant patient characteristics 
Patient characteristics are reported in Table 1. Fifty-three percent (108/203) of the patients had 
NHL, 13% (26/203) had HL and 34% (69/203) had MM. Median age at transplant was 53 years 
(range=17–69). Median number of previous lines of chemotherapy was 3 (range=0–7), which 
included at least one autograft in 68% of the patients. No patient was treated with a planned tandem 
autologous/allogeneic transplantation. Overall, 25% of the patients were transplanted in CR, 50% in 
partial response and 25% in progressive disease. However, most patients with MM were in partial 
response and progressive disease (63/69, 91%), as well as patients with HL (18/26, 69%), whereas 
most patients with NHL were in CR (72/108, 67%). A total of 154/203 (76%) were conditioned to 
transplant with a RIC conditioning, whereas 49/203 (24%) were conditioned with a non-
myeloablative conditioning. The most commonly used RIC was thiotepa–fludarabine–
cyclophosphamide (n=76) for sibling donors and thiotepa–cyclophosphamide–antithymocyte 
globulin (n=62) for unrelated donors. Low-dose total body irradiation with/without fludarabine was 
administered to 49 patients transplanted either from a sibling (n=33) or an unrelated donor (n=16). 
Patients transplanted with a non-myeloablative regimen had more frequently MM (P<0.001), had 
more commonly relapsed after an autograft (P<0.001) and had a lower probability of being in CR at 
transplant (P<0.001; Table 2). Diagnoses were equally distributed among the three centers. 
 
Table 1 - Pretransplant patient characteristics. 
 
 
 
 
 
 
Table 2 - Patient characteristics based on conditioning regimen. 
 
 
Patients were divided into three groups in the light of the HCT-CI at transplant: 0 (32%, 65/203), 1–
2 (31%, 62/203) and 3 (37%, 76/203). Median HCT-CI was 2 (range=0–8). The most common 
comorbidities involved pulmonary (39%) and cardiac functions (14%) and active infections at the 
time of transplant (14%; Table 3). Karnofsky PS was >80% in 60% (123/203) and 80% in 40% 
(80/203) of the patients with a median value of 90% (range=40–100). 
 
 
 
 
 
 
 
 
 
 
 
Table 3 - Absolute number and rate of each comorbidity according to HCT-CI in 203 
patients. 
 
 
Clinical outcomes 
Median follow-up was 20 months (range=0–93). Overall, NRM cumulative incidence was 15% at 1 
year and 18% at 2 years. For patients with an HCT-CI of 0, 1- and 2-year cumulative NRM were 5 
and 6%, respectively, whereas for patients with an HCT-CI of 1–2 and 3, a 1-year NRM of 16 and 
20%, and a 2-year NRM of 24 and 27% were observed, respectively (P=0.04; Figure 1a). NRM 
was not different between patients with HCT-CI of 1–2 and HCT-CI of 3 (P=0.48). By univariate 
analysis, the Karnofsky PS also influenced NRM: patients with a Karnofsky PS >80% had 1- and 2-
year NRM of 10 and 12%, respectively, as compared to 24 and 28% of patients with a lower 
Karnofsky PS (P=0.02). Other factors that significantly affected NRM were age (<55 vs 55, 
P=0.048) and donor type (sibling vs matched unrelated, P=0.02). A previous autograft, the number 
of previous lines of chemotherapy, the conditioning regimen, diagnosis and pretransplant disease 
status were not statistically significant (Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cumulative non-relapse mortality (NRM), overall survival (OS) and progression-
free survival (PFS) by pretransplant HCT-CI. (a) NRM (P=0.04), (b) OS (P< 0.001) and (c) 
PFS (P<0.001).  
 
 
 
 
 
 
 
 
Table 4 - Univariate analysis. 
 
 
Variables included in multivariate analysis were age (<55 vs 55), HCT-CI (0 vs 1–2 vs 3), 
Karnofsky PS (>80 vs 80%), diagnosis (lymphomas vs MM), disease status at transplant (CR vs 
no-CR), the number of previous lines of therapy ( 2 vs >2), a previous autograft ( 1 vs 0), donor 
type (sibling vs unrelated) and the conditioning regimen (non-myeloablative vs RIC; Table 5). By 
multivariate analysis, a high HCT-CI (HR=1.60, P=0.03) and a low Karnofsky PS (HR=2.12, 
P=0.04) and the diagnosis of lymphoma (HR=0.31 for MM, P=0.002) were correlated with a 
significantly higher NRM. 
 
Table 5 - Cox multivariate analysis. 
 
 
Overall survival was higher in patients with lower HCT-CI: 1- and 2-year OS were 89 and 87%, 
respectively for an HCT-CI of 0 as compared to 65 and 51% for an HCT-CI of 1–2, and 59 and 
49% for an HCT-CI of 3 (P<0.001; Figure 1b). OS did not significantly differ between patients 
with HCT-CI of 1–2 and patients with HCT-CI of 3 (P=0.46). By univariate analysis, OS was 
also influenced by the Karnofsky PS (P<0.001), the number of previous lines of therapy (P=0.02), 
pretransplant disease status (P=0.007) and age at transplant (P=0.02; Table 4). By multivariate 
analysis, only the HCT-CI and the Karnofsky PS significantly predicted OS (HR=1.62, P<0.001 
and HR=3.10, P<0.001, respectively; Table 5). 
By univariate analysis, the HCT-CI and the Karnofksy PS (P<0.001), pretransplant disease status 
and the number of previous lines of therapy (P=0.01) were also significant for PFS (Table 4). PFS 
of patients with HCT-CI of 1–2 was not significantly different compared to patients with HCT-CI 
of 3 (P=0.13). By multivariate analysis, only the HCT-CI was statistically significant (HR=1.43, 
P=0.002), whereas there was only a trend for the Karnofsky PS (HR=1.44, P=0.07; Table 5). 
Lymphoma and myeloma subgroup analyses 
For patients with lymphomas, 1- and 2-year NRMs were 17 and 21%, respectively and significantly 
higher in patients with (i) an HCT-CI score 3 (6% at 1 year and 6% at 2 years for an HCT-CI of 0, 
14 and 20% for an HCT-CI of 1–2, 30 and 35% for an HCT-CI of 3; P=0.03; Figure 2a); (ii) a 
lower Karnofsky PS (7% at 1 year and 10% at 2 years for Karnofsky PS >80, 37 and 42% for 
Karnofsky PS 80%, P<0.001); (iii) age 55 (P=0.007); (iv) a transplant from an unrelated donor 
(P=0.04). OS was 71% at 1 year and 61% at 2 years and significantly longer in patients with an 
HCT-CI of 0 (91% at 2 years, P<0.001) as compared to patients with an HCT-CI of 1–2 or 3 (54 
and 37% at 2 years, respectively). Other factors that influenced OS were the Karnofsky PS 
(P<0.001), pre-transplant disease status (P=0.01) and the conditioning (P=0.03, worse survival in 
the non-myeloablative group). One- and 2-year PFS were 53 and 46%, respectively. PFS was 
significantly correlated with HCT-CI (2-year PFS 69% for an HCT-CI of 0, 47% for an HCT-CI of 
1–2, 23% for an HCT-CI of 3, P<0.001), the Karnofsky PS (P<0.001) and pretransplant disease 
status (P=0.04). Patients with NHL had a RI of 25% at 1 year and 30% at 2 years, whereas patients 
with HL had a RI of 27% at 1 year and 39% at 2 years (Figure 3a and b). 
 
Figure 2.Non-relapse mortality (NRM) for patients with lymphomas and myeloma by 
pretransplant HCT-CI. (a) NRM for lymphomas (P=0.03) and (b) NRM for myeloma (P=0.3). 
 
  
Figure 3. Cumulative incidence of relapse (RI) in non-Hodgkin's lymphoma (NHL), 
Hodgkin's lymphoma (HL) and multiple myeloma (MM) patients. (a) RI in NHL, (b) RI in 
HL and (c) RI in MM. 
 
 For patients with MM, NRM was 12 and 13% at 1 and 2 years, respectively. NRM was not 
significantly different between patients with an HCT-CI of 0 (0% at 1 year and 5% at 2 years) vs 
those with a higher HCT-CI (20% at 1 and 2 years for HCT-CI of 1–2 and 12% at 1 and 2 years for 
HCT-CI of 3, respectively; P=0.3; Figure 2b). The 1-and 2-year OS were 71 and 64%, 
respectively. Patients with an HCT-CI of 0 and a Karnofsky PS >80% showed a slightly better OS 
(P=0.09 and P=0.07, respectively) that was significantly influenced by a previous autograft 
(P<0.02). PFS was predicted by the number of previous lines of therapy (P=0.002) and a previuos 
autograft (P=0.02), but not by a high HCT-CI (P=0.24) or low Karnofsky PS (P=0.91). Patients 
with MM had a RI of 33% at 1 year and 45% at 2 years (Figure 3c). 
Correlation of HCT-CI with other clinical factors 
Hematopoietic cell transplantation comorbidity index was not correlated with age (P=0.38), time 
from diagnosis to transplant (P=0.68) and pretransplant disease status (P=0.73). A significant 
correlation was found between the HCT-CI and the Karnofsky PS (P<0.001, rho=-0.34) and 
between the HCT-CI and the number of previous lines of therapy (P=0.002, =0.21). 
Overall incidence of grade II–IV acute GVHD was 33%. For patients with an HCT-CI of 0, 1–2, 
and 3, the incidence was 29, 34 and 36%, respectively. By univariate analysis, we did not observe 
any statistically significant correlation between acute GVHD and the presence of comorbidities 
(P=0.72). The incidence of chronic GVHD was 30% at 1 year. Patients with an HCT-CI of 0, 1–2 
and 3 had an incidence of 31, 28 and 26%, respectively (P=0.77). 
HCT-CI and conditioning regimens 
In the RIC group, 1- and 2-year NRM cumulative incidence was 6 and 8% for an HCT-CI of 0, 15 
and 20% for an HCT-CI of 1–2 and 20 and 25% for an HCT-CI of 3 respectively (P=0.27). The 
1- and 2-year NRM were 8 and 10% for Karnofsky PS >80 and 20 and 31% for Karnofsky PS 
80%, respectively (P=0.01). PFS was influenced by the HCT-CI (P=0.006) and Karnofsky PS 
(P<0.001). OS was significantly worse for an HCT-CI score 3 (P=0.001) and a Karnofsky PS 80 
(P<0.001; Figure 4a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. Overall survival (OS) of patients treated with an allograft after a RIC or a non-
myeloablative regimen stratified by the HCT-CI. (a) OS after a RIC allograft (P=0.001) and 
(b) OS after a non-myeloablative allograft (P=0.02). 
 
 
In the non-myeloablative group, the cumulative incidence of NRM at 1 and 2 years was 0% for 
patients with an HCT-CI score of 0, 20% for HCT-CI of 1–2, and 33% for HCT-CI score of 3, 
respectively (P=0.06). NRM for patients with a Karnofsky PS >80 was 17% at both 1 and 2 years, 
whereas for patients with a Karnofsky PS 80%, it was 23% at both 1 and 2 years (P=0.58). PFS 
was not correlated either with the HCT-CI or the Karnofsky PS (P=0.09 and P=0.58, respectively). 
OS was significantly reduced according to HCT-CI category (P=0.02), whereas it was not 
influenced by Karnofsky PS (P=0.12; Figure 4b). However, regardless of the conditioning regimen 
used, in patients with the same HCT-CI of 0, HCT-CI of 1–2 or HCT-CI of 3, there was no 
significant difference in NRM (P=0.19 for HCT-CI=0, P=0.87 for HCT-CI=1–2, P=0.33 for HCT-
CI of 3), in OS (P=0.94 for HCT-CI=0, P=0.76 for HCT-CI=1–2, P=0.18 for HCT-CI of 3) and 
in PFS (P=0.55 for HCT-CI=0, P=0.62 for HCT-CI=1–2, P=0.19 for HCT-CI of 3). 
 
Discussion 
Patients with lymphomas and myeloma are often not eligible for a standard myeloablative allograft 
because of age 55 years, comorbidities and/or the intensity of previous therapies. Though 
allografting after RIC or non-myeloablative regimens is now feasible in elderly and/or medically 
unfit patients, the risk of NRM remains a relevant issue. Our retrospective study aimed at providing 
a valid tool to assess transplant-related risks and help physicians in the decision-making process 
when patients with lymphomas or MM are evaluated for an allograft. For this purpose, we evaluated 
a cohort of 203 consecutive patients treated with an allograft at three Italian transplant centers with 
a large experience on the treatment of lymphomas and MM. 
The Seattle group
23
 recently showed that 1- and 2-year NRM and OS are significantly better for 
patients with an HCT-CI of 0 compared to patients with an HCT-CI of 1–2 or 3. Moreover, the 
study clearly suggested that NRM of patients with an HCT-CI of 0 is as low as that observed 
following an autograft and that even the presence of a single comorbidity can significantly affect 
post-transplant outcome. Other groups tested the reproducibility of HCT-CI, and some discordant 
results have been reported.
24, 25
 Xhaard et al.
24
 assessed the impact of HCT-CI on the outcome of 
patients receiving either a RIC or a myeloablative conditioning for several hematological diseases. 
In this study, HCT-CI was not predictive of NRM and OS but, as the authors highlighted, 70% of 
pulmonary function tests were lacking and this may have prevented complete analyses and 
comparisons with other patient characteristics. In our series, all patients were evaluated for all the 
comorbidities included in the HCT-CI score, and 39% of them had abnormal pulmonary function 
tests, suggesting the relevant role of this parameter. The Canadian group reported that Karnofsky 
PS, but not HCT-CI was predictive for outcome in 187 patients undergoing an allogeneic stem cell 
transplantation.
25
 Patient characteristics, including disease types, age at transplant and conditioning 
regimens were largely different from our study, making any comparison impossible. Furthermore, 
the long period during which transplants were performed (from 1991 to 2006) may have affected 
clinical outcomes given the significant improvement in supportive care. The authors also suggested 
that owing to international discrepancies in healthcare, the universality of the HCT-CI may be 
controversial. Nevertheless, our multicenter analysis, performed at European Centers, confirmed the 
results of the Seattle group. We observed a significant difference in OS, NRM and also in PFS 
between patients with HCT-CI of 0 compared to patients with HCT-CI of 1–2 and 3. The 
predictive value of the HCT-CI for OS was confirmed for both RIC and non-myeloablative 
regimens. Importantly, multivariate analyses showed that the HCT-CI, the Karnofsky PS and the 
diagnosis were the only significant variables to predict NRM. These findings are rather encouraging 
as they confirm the reliability and the reproducibility of these simple tools to evaluate transplant-
related risks and underline that age is not an independent predictor of NRM, as reported 
previously.
9, 10, 11
 
The fact that outcomes between HCT-CI of 1–2 and 3 were not significantly different can suggest 
two considerations: first, the sensitivity of HCT-CI could be improved to detect differences among 
patients with increasing number of comorbidities; second, further studies should be focused to 
decrease NRM in patients with one or two comorbidities receiving a RIC or non-myeloablative 
allogeneic stem cell transplantation. A recently published study by the Minnesota group aimed at 
showing the feasibility of cord blood transplant in patients above 55 years has reported worse NRM, 
OS and PFS for patients with HCT-CI 3, whereas patients with HCT-CI of 0 and 1–2 had similar 
outcomes.
26
 In this study, patient characteristics were highly different from our series with regard to 
age, diagnosis type, stem cell sources, the number of prior autologous transplants and conditioning 
regimens. In particular, the use of cord blood and age over 55 years may have increased NRM in 
HCT-CI of 0 (6-month TRM 14%) reducing the gap with HCT-CI of 1–2. Moreover, TRM was 
defined as death within 180 days, which greatly differs from our definitions. 
Patients with at least one comorbidity experienced a worse PFS compared to those without. 
Interestingly, we noticed that the number of previous lines of chemotherapies correlated with a 
higher HCT-CI. Sorror et al.
16
 observed that patients with a higher HCT-CI had also a higher 
relapse risk. However, no correlation between the HCT-CI and the number of previous 
chemotherapies was reported in their study. Furthermore, in contrast with other studies,
16, 27
 we did 
not observe any correlation between age and HCT-CI. Our finding may be due to the fact that our 
patients had failed several lines of therapies, including, in most cases, an autograft. Therefore, the 
intensity of the treatment may have determined the comorbidities, such as an impaired pulmonary 
function, that significantly affect NRM regardless of patient age. In summary, our results support 
the notion that the higher the number of pre-transplant treatments, the higher the presence of 
comorbidities at transplant and fewer the chances of long-term disease control with acceptable 
toxicity. We find these data of interest as they clearly show that an appropriate timing for 
allografting in the treatment plan of lymphomas and MM is fundamental to improve clinical 
outcomes in the future. 
In the subgroup analysis by disease diagnosis, NRM and OS were better for patients with an HCT-
CI of 0, although this difference was not statistically significant in MM. The fact that only 9% of 
the patients affected by myeloma were in CR/nCR at transplant compared to 67% for patients 
affected by NHL can explain the lack of significance of disease stage in predicting PFS for MM. 
The advanced disease and the high relapse incidence along with the limited number of patients can 
also explain the lack of significance of HCT-CI in this setting. 
As previously reported by the Seattle group, the Karnofsky PS was inversely correlated with the 
HCT-CI
16
 and was strongly correlated with NRM and OS, and, to a lesser extent, with PFS. As 
observed for HCT-CI, the minor influence on PFS may be due to the high rate of progression in 
MM patients, whereas Karnofsky PS was significantly correlated with PFS in lymphomas. 
We initially hypothesized that the incidence of GVHD may have been correlated with comorbidities 
as organ damage may predispose to untoward immune responses.
28, 29
 However, no significant 
correlation between grade II and IV acute or chronic GVHD and the HCT-CI has been observed, 
although there was a slight increase of acute GVHD in patients with an HCT-CI score of 1. 
Finally, though the diagnoses were not equally distributed between the RIC group and the non-
myeloablative group, which comprised more patients with MM who had undergone a previous 
autograft, we did not observe any impact of the HCT-CI on outcomes, such as NRM and OS, with 
respect to the conditioning used. These results support the feasibility of a wide range of 
conditionings in lymphoprolipherative disorders regardless of patient age and number of 
comorbidities. 
In conclusion, our study shows that the HCT-CI is a simple and reliable tool to predict NRM, OS 
and partly PFS in patients with lymphomas and MM undergoing a RIC or a non-myeloablative 
allograft in a multicenter setting. Taking into account the limits of a retrospective analysis, our 
results suggest that the HCT-CI should invariably be part of the pretransplant work-up to evaluate 
transplant-related risks in all prospective control trials and help define those patients who may 
benefit most from an allograft. 
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